Cygnus is one of 1999's few great turnaround stories. A year ago, it was on the verge of collapse, but now it is about to get FDA approval of the first non-invasive glucose monitor for diabetes. Next, Cygnus needs to find a corporate partner without giving up too much, and to determine the true market potential of its device, the GlucoWatch Biographer, which got approved as an adjunct to, not a replacement for, traditional blood-glucose testing.
By Wendy Diller
The December 6 meeting of the FDA Clinical Chemistry and Clinical Toxicology Devices Panel had a buoyant atmosphere. Several parents...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
